Mycophenolate mofetil versus azathioprine therapy is associated with a significant protection against long-term renal allograft function deterioration

Herwig Ulf Meier-Kriesche, Bettina J. Steffen, Alan M. Hochberg, Robert D. Gordon, Michael N. Liebman, Jonathan A. Morris, Bruce Kaplan

Research output: Contribution to journalArticle

127 Citations (Scopus)

Abstract

Background. To evaluate the association of longterm continuous mycophenolate mofetil (MMF) versus azathioprine (AZA) therapy and renal allograft function, as measured by the slope of reciprocal creatinine, we analyzed 49,666 primary renal allograft recipients reported to the United States Renal Data System between October 31, 1988 and June 30, 1998. Methods. The primary study endpoint was defined as a greater than 20% decrease below a 6-month baseline of 1/serum creatinine (SCr) (slope of reciprocal creatinine) at or beyond 1 year after transplantation. A secondary endpoint was defined as reaching an SCr value greater than 1.6 mg/dL. Univariate Kaplan-Meier analysis and multivariate Cox proportional hazard models were used to investigate the risk of reaching the study endpoints. Multivariate analyses were corrected for potential confounding covariates. Results. According to the Cox proportional hazard model, 12-month continued therapy of MMF versus AZA was associated with a protective effect against declining renal function, as measured by the slope of reciprocal creatinine (relative risk [RR]=0.84, confidence interval 0.78-0.91, P

Original languageEnglish (US)
Pages (from-to)1341-1346
Number of pages6
JournalTransplantation
Volume75
Issue number8
DOIs
StatePublished - Apr 27 2003
Externally publishedYes

Fingerprint

Mycophenolic Acid
Azathioprine
Allografts
Creatinine
Kidney
Proportional Hazards Models
Therapeutics
Kaplan-Meier Estimate
Serum
Information Systems
Multivariate Analysis
Transplantation
Confidence Intervals

ASJC Scopus subject areas

  • Transplantation
  • Immunology

Cite this

Meier-Kriesche, H. U., Steffen, B. J., Hochberg, A. M., Gordon, R. D., Liebman, M. N., Morris, J. A., & Kaplan, B. (2003). Mycophenolate mofetil versus azathioprine therapy is associated with a significant protection against long-term renal allograft function deterioration. Transplantation, 75(8), 1341-1346. https://doi.org/10.1097/01.TP.0000062833.14843.4B

Mycophenolate mofetil versus azathioprine therapy is associated with a significant protection against long-term renal allograft function deterioration. / Meier-Kriesche, Herwig Ulf; Steffen, Bettina J.; Hochberg, Alan M.; Gordon, Robert D.; Liebman, Michael N.; Morris, Jonathan A.; Kaplan, Bruce.

In: Transplantation, Vol. 75, No. 8, 27.04.2003, p. 1341-1346.

Research output: Contribution to journalArticle

Meier-Kriesche, Herwig Ulf ; Steffen, Bettina J. ; Hochberg, Alan M. ; Gordon, Robert D. ; Liebman, Michael N. ; Morris, Jonathan A. ; Kaplan, Bruce. / Mycophenolate mofetil versus azathioprine therapy is associated with a significant protection against long-term renal allograft function deterioration. In: Transplantation. 2003 ; Vol. 75, No. 8. pp. 1341-1346.
@article{2ac6c4bc5e264de79a36febdfb35f870,
title = "Mycophenolate mofetil versus azathioprine therapy is associated with a significant protection against long-term renal allograft function deterioration",
abstract = "Background. To evaluate the association of longterm continuous mycophenolate mofetil (MMF) versus azathioprine (AZA) therapy and renal allograft function, as measured by the slope of reciprocal creatinine, we analyzed 49,666 primary renal allograft recipients reported to the United States Renal Data System between October 31, 1988 and June 30, 1998. Methods. The primary study endpoint was defined as a greater than 20{\%} decrease below a 6-month baseline of 1/serum creatinine (SCr) (slope of reciprocal creatinine) at or beyond 1 year after transplantation. A secondary endpoint was defined as reaching an SCr value greater than 1.6 mg/dL. Univariate Kaplan-Meier analysis and multivariate Cox proportional hazard models were used to investigate the risk of reaching the study endpoints. Multivariate analyses were corrected for potential confounding covariates. Results. According to the Cox proportional hazard model, 12-month continued therapy of MMF versus AZA was associated with a protective effect against declining renal function, as measured by the slope of reciprocal creatinine (relative risk [RR]=0.84, confidence interval 0.78-0.91, P",
author = "Meier-Kriesche, {Herwig Ulf} and Steffen, {Bettina J.} and Hochberg, {Alan M.} and Gordon, {Robert D.} and Liebman, {Michael N.} and Morris, {Jonathan A.} and Bruce Kaplan",
year = "2003",
month = "4",
day = "27",
doi = "10.1097/01.TP.0000062833.14843.4B",
language = "English (US)",
volume = "75",
pages = "1341--1346",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "8",

}

TY - JOUR

T1 - Mycophenolate mofetil versus azathioprine therapy is associated with a significant protection against long-term renal allograft function deterioration

AU - Meier-Kriesche, Herwig Ulf

AU - Steffen, Bettina J.

AU - Hochberg, Alan M.

AU - Gordon, Robert D.

AU - Liebman, Michael N.

AU - Morris, Jonathan A.

AU - Kaplan, Bruce

PY - 2003/4/27

Y1 - 2003/4/27

N2 - Background. To evaluate the association of longterm continuous mycophenolate mofetil (MMF) versus azathioprine (AZA) therapy and renal allograft function, as measured by the slope of reciprocal creatinine, we analyzed 49,666 primary renal allograft recipients reported to the United States Renal Data System between October 31, 1988 and June 30, 1998. Methods. The primary study endpoint was defined as a greater than 20% decrease below a 6-month baseline of 1/serum creatinine (SCr) (slope of reciprocal creatinine) at or beyond 1 year after transplantation. A secondary endpoint was defined as reaching an SCr value greater than 1.6 mg/dL. Univariate Kaplan-Meier analysis and multivariate Cox proportional hazard models were used to investigate the risk of reaching the study endpoints. Multivariate analyses were corrected for potential confounding covariates. Results. According to the Cox proportional hazard model, 12-month continued therapy of MMF versus AZA was associated with a protective effect against declining renal function, as measured by the slope of reciprocal creatinine (relative risk [RR]=0.84, confidence interval 0.78-0.91, P

AB - Background. To evaluate the association of longterm continuous mycophenolate mofetil (MMF) versus azathioprine (AZA) therapy and renal allograft function, as measured by the slope of reciprocal creatinine, we analyzed 49,666 primary renal allograft recipients reported to the United States Renal Data System between October 31, 1988 and June 30, 1998. Methods. The primary study endpoint was defined as a greater than 20% decrease below a 6-month baseline of 1/serum creatinine (SCr) (slope of reciprocal creatinine) at or beyond 1 year after transplantation. A secondary endpoint was defined as reaching an SCr value greater than 1.6 mg/dL. Univariate Kaplan-Meier analysis and multivariate Cox proportional hazard models were used to investigate the risk of reaching the study endpoints. Multivariate analyses were corrected for potential confounding covariates. Results. According to the Cox proportional hazard model, 12-month continued therapy of MMF versus AZA was associated with a protective effect against declining renal function, as measured by the slope of reciprocal creatinine (relative risk [RR]=0.84, confidence interval 0.78-0.91, P

UR - http://www.scopus.com/inward/record.url?scp=0242417526&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0242417526&partnerID=8YFLogxK

U2 - 10.1097/01.TP.0000062833.14843.4B

DO - 10.1097/01.TP.0000062833.14843.4B

M3 - Article

VL - 75

SP - 1341

EP - 1346

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 8

ER -